(ESTA) Establishment Labs Holdings - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 2.125m USD | Total Return: 96.9% in 12m

Breast Implants, Tissue Expanders, Medical Devices
Total Rating 46
Safety 34
Buy Signal 0.11
Medical Devices
Industry Rotation: +5.3
Market Cap: 2.12B
Avg Turnover: 30.0M
Risk 3d forecast
Volatility59.6%
VaR 5th Pctl9.79%
VaR vs Median-0.19%
Reward TTM
Sharpe Ratio1.39
Rel. Str. IBD80.3
Rel. Str. Peer Group76.1
Character TTM
Beta1.460
Beta Downside1.331
Hurst Exponent0.413
Drawdowns 3y
Max DD70.21%
CAGR/Max DD0.06
CAGR/Mean DD0.12
EPS (Earnings per Share) EPS (Earnings per Share) of ESTA over the last years for every Quarter: "2021-03": -0.29, "2021-06": -0.22, "2021-09": -0.61, "2021-12": -0.6, "2022-03": -0.24, "2022-06": -1.52, "2022-09": -0.76, "2022-12": -0.55, "2023-03": -0.48, "2023-06": -0.65, "2023-09": -1.12, "2023-12": -0.79, "2024-03": -0.58, "2024-06": -0.62, "2024-09": -0.59, "2024-12": -1.19, "2025-03": -0.7, "2025-06": -0.56, "2025-09": -0.38, "2025-12": -0.09, "2026-03": -0.4,
Last SUE: -0.09
Qual. Beats: 0
Revenue Revenue of ESTA over the last years for every Quarter: 2021-03: 30.336, 2021-06: 31.994, 2021-09: 29.039, 2021-12: 35.313, 2022-03: 38.452, 2022-06: 41.19, 2022-09: 38.245, 2022-12: 43.813, 2023-03: 46.524, 2023-06: 48.561, 2023-09: 38.506, 2023-12: 31.56, 2024-03: 37.167, 2024-06: 44.117, 2024-09: 40.227, 2024-12: 44.514, 2025-03: 41.377, 2025-06: 51.3, 2025-09: 53.782, 2025-12: 64.617, 2026-03: 59.877,
Rev. CAGR: 9.54%
Rev. Trend: 64.9%
Last SUE: 4.00
Qual. Beats: 1

Warnings

Interest Coverage Ratio -1.1 is critical

Altman Z'' -2.47 < 1.0 - financial distress zone

Choppy

Tailwinds

No distinct edge detected

Description: ESTA Establishment Labs Holdings

Establishment Labs Holdings Inc. (ESTA) is a medical technology firm specializing in the design and manufacture of silicone gel-filled breast implants and tissue expanders. Operating primarily through its Motiva Implants brand, the company serves the global aesthetic and reconstructive plastic surgery markets across over 80 countries. Its distribution model utilizes a mix of direct sales forces and independent distributors to reach clinics and hospitals.

The company operates within the Health Care Supplies sub-industry, where product adoption is heavily influenced by regulatory approvals and long-term clinical safety data. Unlike traditional manufacturers, ESTA integrates proprietary technologies such as radio-frequency identification (RFID) microchips into its devices to enhance product traceability and patient safety.

Investors can find further analysis of the companys valuation and market positioning on ValueRay. Establishment Labs remains headquartered in Austin, Texas, and continues to expand its footprint in the United States and international markets through ongoing clinical trials and regulatory submissions.

Headlines to Watch Out For
  • FDA approval and commercial launch of Motiva Implants in the United States
  • Revenue growth acceleration through direct sales expansion in high-value European markets
  • Adoption of Mia Femtech minimally invasive technology across international surgical centers
  • Manufacturing scalability and gross margin improvements at Costa Rica production facilities
  • Regulatory compliance and safety data monitoring for silicone gel-filled breast implants
Piotroski VR-10 (Strict) 2.5
Net Income: -43.7m TTM > 0 and > 6% of Revenue
FCF/TA: -0.12 > 0.02 and ΔFCF/TA 10.99 > 1.0
NWC/Revenue: 70.86% < 20% (prev 95.55%; Δ -24.69% < -1%)
CFO/TA -0.10 > 3% & CFO -34.8m > Net Income -43.7m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.96 > 1.5 & < 3
Outstanding Shares: last quarter (29.6m) vs 12m ago 0.50% < -2%
Gross Margin: 70.06% > 18% (prev 0.66%; Δ 6.94k% > 0.5%)
Asset Turnover: 67.09% > 50% (prev 51.07%; Δ 16.02% > 0%)
Interest Coverage Ratio: -1.08 > 6 (EBITDA TTM -18.0m / Interest Expense TTM 26.5m)
Altman Z'' -2.47
A: 0.46 (Total Current Assets 245.8m - Total Current Liabilities 83.2m) / Total Assets 351.0m
B: -1.45 (Retained Earnings -509.1m / Total Assets 351.0m)
C: -0.08 (EBIT TTM -28.6m / Avg Total Assets 342.2m)
D: -0.21 (Book Value of Equity -72.2m / Total Liabilities 336.3m)
Altman-Z'' = -2.47 = D
Beneish M -2.78
DSRI: 0.90 (Receivables 77.1m/63.2m, Revenue 229.6m/170.2m)
GMI: 0.95 (GM 70.06% / 66.35%)
AQI: 1.26 (AQ_t 0.08 / AQ_t-1 0.06)
SGI: 1.35 (Revenue 229.6m / 170.2m)
TATA: -0.03 (NI -43.7m - CFO -34.8m) / TA 351.0m)
Beneish M = -2.78 (Cap -4..+1) = A
What is the price of ESTA shares?

As of May 27, 2026, the stock is trading at USD 72.64 with a total of 575,427 shares traded.
Over the past week, the price has changed by +10.68%, over one month by +10.95%, over three months by -5.85% and over the past year by +96.88%.

Is ESTA a buy, sell or hold?

Establishment Labs Holdings has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy ESTA.

  • StrongBuy: 5
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the ESTA price?
Analysts Target Price 90.1 24.1%
Establishment Labs Holdings (ESTA) - Fundamental Data Overview as of 27 May 2026
Market Cap USD = 2.12b (2.12b USD * 1.0 USD.USD)
P/S = 9.2544
P/B = 143.658
Revenue TTM = 229.6m USD
EBIT TTM = -28.6m USD
EBITDA TTM = -18.0m USD
Long Term Debt = 248.6m USD (from longTermDebt, last quarter)
Short Term Debt = 13.0m USD (from shortTermDebt, last quarter)
Debt = 268.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 4.12m
Net Debt = 200.0m USD (calculated: Debt 268.1m - CCE 68.1m)
Enterprise Value = 2.32b USD (2.12b + Debt 268.1m - CCE 68.1m)
Interest Coverage Ratio = -1.08 (Ebit TTM -28.6m / Interest Expense TTM 26.5m)
EV/FCF = -55.19x (Enterprise Value 2.32b / FCF TTM -42.1m)
FCF Yield = -1.81% (FCF TTM -42.1m / Enterprise Value 2.32b)
FCF Margin = -18.35% (FCF TTM -42.1m / Revenue TTM 229.6m)
Net Margin = -19.05% (Net Income TTM -43.7m / Revenue TTM 229.6m)
Gross Margin = 70.06% ((Revenue TTM 229.6m - Cost of Revenue TTM 68.7m) / Revenue TTM)
Gross Margin QoQ = 70.70% (prev 70.46%)
Tobins Q-Ratio = 6.62 (Enterprise Value 2.32b / Total Assets 351.0m)
Interest Expense / Debt = 9.88% (Interest Expense 26.5m / Debt 268.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -22.6m (EBIT -28.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.96 (Total Current Assets 245.8m / Total Current Liabilities 83.2m)
Debt / Equity = 18.13 (Debt 268.1m / totalStockholderEquity, last quarter 14.8m)
 Debt / EBITDA = -11.13 (negative EBITDA) (Net Debt 200.0m / EBITDA -18.0m)
 Debt / FCF = -4.75 (negative FCF - burning cash) (Net Debt 200.0m / FCF TTM -42.1m)
 Total Stockholder Equity = 19.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.78% (Net Income -43.7m / Total Assets 351.0m)
RoE = -8.28% (Net Income TTM -43.7m / Total Stockholder Equity 528.5m)
RoCE = -3.68% (EBIT -28.6m / Capital Employed (Equity 528.5m + L.T.Debt 248.6m))
 RoIC = -10.61% (negative operating profit) (NOPAT -22.6m / Invested Capital 212.7m)
 WACC = 10.75% (E(2.12b)/V(2.39b) * Re(11.12%) + D(268.1m)/V(2.39b) * Rd(9.88%) * (1-Tc(0.21)))
Discount Rate = 11.12% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.45 | Cagr: 5.85%
 [DCF] Fair Price = unknown (Cash Flow -42.1m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.09 | # QB: 0
Revenue Correlation: 64.92 | Revenue CAGR: 9.54% | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.30 | Chg30d=-6.38% | Revisions=+20% | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.23 | Chg30d=+21.67% | Revisions=-20% | Analysts=2
EPS current Year (2026-12-31): EPS=-1.01 | Chg30d=+3.03% | Revisions=+20% | GrowthEPS=+41.7% | GrowthRev=+26.7%
EPS next Year (2027-12-31): EPS=0.07 | Chg30d=-62.96% | Revisions=-20% | GrowthEPS=+107.4% | GrowthRev=+26.2%
[Analyst] Revisions Ratio: +20%